Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Alembic Pharmaceuticals Limited develops, manufactures, and markets pharmaceutical products in India and internationally. The company provides branded specialty medicines in various therapeutic areas, such as cardiology, gynecology, gastrology, ophthalmology, dermatology, nephrology/urology, orthopedics, anti-infective, cold and cough, veterinary, and anti-diabetic; generics formulations in oral solids, oncology oral solids and injectables, general injectables and ophthalmic products, dermatology, and oral suspension; and active pharmaceutical ingredients. It also exports its products. The company was founded in 1907 and is headquartered in Vadodara, India.

Revenue projections:

Revenue projections for APLLTD
Revenue projections for APLLTD

APLLTD's projected revenue decline from last year is likely to make investors cautious. Lower revenues often hurt a company's bottom line, leading investors to be concerned about the company's ability to maintain profitability and deliver strong financial results in the future.

Financial Ratios:

currentRatio 0.00000
forwardPE 22.53996
debtToEquity 21.81700
earningsGrowth -0.23600
revenueGrowth 0.03800
grossMargins 0.73156
operatingMargins 0.11236
trailingEps 30.72000
forwardEps 43.50000

With APLLTD's Forward PE in a favorable range, the stock appears reasonably priced compared to its earnings. This suggests that it's not overpriced and there is room for growth, providing an encouraging opportunity for investors seeking future value increases.
APLLTD's low Debt-to-Equity ratio highlights its minimal reliance on debt, showing that the company is not over-leveraged. This contributes to lower financial risk and greater stability, giving APLLTD a stronger position in managing its financial obligations.
APLLTD's low earnings and revenue growth indicate potential profit shrinkage. This suggests that the company's financial performance may be weakening, raising concerns about its future profitability and overall business outlook.
Alembic Pharmaceuticals Limited's negative gross and operating margins indicate the company is operating at a loss, unable to generate profit from its core business activities. This suggests financial strain and potential challenges in maintaining profitability.
Alembic Pharmaceuticals Limited's forward EPS surpasses its trailing EPS, indicating that the company is expected to be more profitable in the current financial year. This reflects growing confidence in Alembic Pharmaceuticals Limited's earnings potential, suggesting stronger financial performance compared to the previous year.

Price projections:

Price projections for APLLTD
Price projections for APLLTD

Alembic Pharmaceuticals Limited's price projections have consistently been revised higher, indicating growing confidence in the company's future potential. Analysts appear more optimistic about Alembic Pharmaceuticals Limited's ability to generate strong results going forward.

Insider Transactions:

Insider Transactions for APLLTD
Insider Transactions for APLLTD


Alembic Pharmaceuticals Limited saw 11 buy transactions, with market price of 835.5045443448154.During the review period, no buy transactions were executed.APLLTD's current price levels are marked by more sells than buys, potentially signaling a price decline. If this trend continues, it may suggest that investors expect the stock to drop further in value.

Recommendation changes over time:

Recommendations trend for APLLTD
Recommendations trend for APLLTD


Analysts have been favoring APLLTD with a buy bias recently, signaling a promising investment opportunity. This optimistic outlook may attract more investors, positioning APLLTD as a desirable option for those seeking to invest their money in a stable, profitable company with strong growth potential.